Global Neoantigen Peptides Manufacturing Market

Report ID : 1270 | Published : 2022-11-18 | Pages: 170 | Format: PDF/EXCEL

Global Neoantigen Peptides Manufacturing Market is projected to grow at a compound annual growth rate (CAGR) of 16.4% from 2022 to 2030. Neoantigens are newly generated peptides that are capable of inducing tumour-specific T cell recognition. These are created through somatic mutations. Researchers and physicians have recently used next-generation sequencing technology to detect neoantigens and develop tailored cancer immunotherapies. Neoantigens are short peptides derived from tumour-specific somatic mutations. These peptides bind to HLA (Human Leucocyte Antigen) molecule to be recognized by T-Cell Receptors (TCRs), which further activate the immune system for specific cancer cells. In manufacturing neoantigen-based vaccines, personalized neoantigen peptides are synthesized, which helps induce the T-cell population. This new type of immunotherapy can produce a strong and specific immune response and draw out stable therapeutic effects. As a result, personalized neoantigen peptide vaccines are designed to train a patient's immune system to target and kill tumour cells. Hence they are used to develop vaccines and immunotherapies against cancer cells. These significant neoantigens can control tumour outgrowth and felicitate cellular transformation.

Synthetic peptides are a recognized model of cancer vaccine delivery, but creating the peptides for each patient rapidly and inexpensively remains difficult. The rising number of clinical trials, the growth in cancer and chronic illness cases, and the necessity for long-term therapy for these diseases are all prominent market factors for Neoantigen peptide synthesis. Furthermore, advances in biotechnology research will help researchers better understand individualized neoantigen peptides. Increased external investment in cancer drug research and development, on the other hand, drives the market upward. On the other hand, costly designing and development of personalized cancer therapeutics and delayed clinical trials due to the COVID-19 impact will restrain the market.

The Neoantigen Peptides Manufacturing Market is segmented into the Scale of operations, end-users, and region. The scope of operation segment comprises research/preclinical, clinical, and commercial. The market is segmented into pharmaceutical/vaccine developer companies, contract research organizations (CRO), and academic & research institutes by end-users. Region-wise, the market is studied across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The North American market can witness rapid growth during the forecast period (2020-2030) due to the well-established healthcare infrastructure, growing research regarding Peptide synthesis, and the rising government efforts to develop personalized vaccines.

Major key players operating in the neoantigen peptide manufacturing market are CPC Scientific Inc, Polypeptide group, Genscript Biotech, Kaneka Eurogentec S.A., Vivitide, Almac, BCN Peptides, Creative Peptides, Pepscan, Provepharm, Creosalus, AnaSpec, Gyros Protein Technologies, Other Prominent Players

Companies Mentioned

  • CPC Scientific Inc
  • Polypeptide group
  • Genscript Biotech
  • Kaneka Eurogentec S.A.
  • Vivitide
  • Almac
  • BCN Peptides
  • Creative Peptides
  • Pepscan
  • Provepharm
  • Creosalus
  • Gyros Protein Technologies
  • AnaSpec
  • Other Prominent Players

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Neoantigen Peptides Manufacturing Market Snapshot

Chapter 4. Global Neoantigen Peptides Manufacturing Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Industry Analysis – Porter’s Five Forces Analysis

4.6. Investment and Funding Analysis for Neoantigen Vaccine and Therapeutic Development

4.7. Clinical Trial/Pipeline Analysis for Neoantigen Cancer Vaccine

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Scale of Operations Estimates & Trend Analysis

5.1. By Scale of Operations & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By Scale of Operations:

5.2.1. Research / Preclinical

5.2.2. Clinical

5.2.3. Commercial

Chapter 6. Market Segmentation 2: By End-Users Estimates & Trend Analysis

6.1. By End-Users & Market Share, 2020& 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following By End-Users:

6.2.1. Pharmaceutical/Vaccine Developers Companies

6.2.2. Contract Research Organization (CRO)

6.2.3. Academic and Research Institutes

Chapter 7. Neoantigen Peptides Manufacturing Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts By Scale of Operations, 2019-2030

7.1.2. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts By Therapy, 2019-2030

7.1.3. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2019-2030

7.1.4. North America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by country, 2019-2030

7.2. Europe

7.2.1. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2019-2030

7.2.2. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2019-2030

7.2.3. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2019-2030

7.2.4. Europe Neoantigen Peptides Manufacturing Market revenue (US$ Million) by country, 2019-2030

7.3. Asia Pacific

7.3.1. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2019-2030

7.3.2. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2019-2030

7.3.3. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2019-2030

7.3.4. Asia Pacific Neoantigen Peptides Manufacturing Market revenue (US$ Million) by country, 2019-2030

7.4. Latin America

7.4.1. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2019-2030

7.4.2. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2019-2030

7.4.3. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) estimates and forecasts by End-Users, 2019-2030

7.4.4. Latin America Neoantigen Peptides Manufacturing Market revenue (US$ Million) by country, 2019-2030

7.5. Middle East & Africa

7.5.1. Middle East & Africa Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Scale of Operations, 2019-2030

7.5.2. Middle East & Africa Neoantigen Peptides Manufacturing Market revenue (US$ Million) By Therapy, 2019-2030

Chapter 8. Competitive Landscape  

8.1. Major Mergers and Acquisitions/Strategic Alliances

8.2. Company Profiles

        8.2.1. CPC Scientific Inc

8.2.2. Polypeptide group

8.2.3. Genscript Biotech

8.2.4. Kaneka Eurogentec S.A.

8.2.5. Vivitide

8.2.6. Almac

8.2.7. BCN Peptides

8.2.8. Creative Peptides

8.2.9. Pepscan

8.2.10. Provepharm

8.2.11. Creosalus

8.2.12. Gyros Protein Technologies

8.2.13.AnaSpec

8.2.14. Other Prominent Players

Global Neoantigen Peptides Manufacturing Market, by Scale of operations, 2020-2030 (Value US$ Mn)

  • Research/Preclinical
  • Clinical
  • Commercial

Global Neoantigen Peptides Manufacturing Market, by End-Users 2020-2030 (Value US$ Mn)

  • Pharmaceutical/Vaccine developers companies
  • Contract Research Organizations (CRO)
  • Academic and research institutes

Global Neoantigen Peptides Manufacturing Market, by Region, 2020-2030 (Value US$ Mn)

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

North America Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)

  • U.S.
  • Canada

Europe Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)

  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

Asia Pacific Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Neoantigen Peptides Manufacturing Market, by Country, 2020-2030 (Value US$ Mn)

  • GCC Countries
  • South Africa

Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?

Frequently Asked Questions

Who are the Key Players in the Neoantigen Peptides Manufacturing Market?

2022

CAGR) of 16.4% from 2022 to 2030

Our Clients